Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Akebia Therapeutics (AKBA) Misses Q2 EPS by 19c
August 5, 2021 8:04 AM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.51), $0.19 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $52.9 million versus the consensus estimate of $52.88 million.
"The first half of 2021 has been marked by significant milestones that have further strengthened Akebia's position and the potential market opportunity for vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), setting the stage for an exciting and catalyst-rich year ahead for us. During the quarter, these... More
